<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04031794</url>
  </required_header>
  <id_info>
    <org_study_id>Si 203/2018</org_study_id>
    <nct_id>NCT04031794</nct_id>
  </id_info>
  <brief_title>ECMO for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure</brief_title>
  <official_title>Extracorporeal Membrane Oxygenator (ECMO) for Critically Ill Patients With Respiratory Failure and/or Circulatory Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mahidol University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mahidol University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Extracorporeal membrane oxygenation (ECMO) had been used to treat refractory hypoxemia
      associated with acute respiratory distress syndrome (ARDS). There were reported good outcome
      associated with ECMO for ARDS caused by influenza infection from several ECMO centers.
      However, the outcome of ECMO support in lower ECMO experience center had not been evaluated.
      This study aimed to evaluate the outcome of ECMO, comparing with conventional treatment among
      severe hypoxemic ARDS patients who were admitted in limited ECMO experience hospital.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This registry enroll refractory hypoxemia ARDS patients who met the criteria for veno-venous
      ECMO, according to 2013 Extracorporeal Life Support Organization (ELSO) guideline criteria.
      The definition of refractory hypoxemia was partial pressure of oxygen:fraction of inspire
      oxygen (PaO2/FiO2) &lt;100 with fraction of inspire oxygen (FiO2) &gt;90% despite optimal
      mechanical ventilator support for at least 2 hours.

      The ECMO team was alerted for patient evaluation. The patients, who did not consider as ECMO
      candidate, due to their underlying condition of terminally illness, were excluded.

      The decision to initiate ECMO, or not, is dependent on the conference included the patient or
      the patient first relative, the attending physician and the ECMO team physicians.

      Patients who ECMO is initiated will be classified into ECMO group. Patients who they or their
      1st degree relative do not agree for ECMO initiation will be treated according to standard
      treatment for ARDS, and classified in non-ECMO group.

      The patients in both groups will be follow up until they are discharged from the hospital.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 22, 2019</start_date>
  <completion_date type="Anticipated">July 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 30, 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <target_duration>6 Months</target_duration>
  <primary_outcome>
    <measure>Hospital outcome</measure>
    <time_frame>at least 90 days</time_frame>
    <description>Patient survive until discharge</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28 days mortality</measure>
    <time_frame>28 days</time_frame>
    <description>Patient who dead before 28 days</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Severe Acute Respiratory Distress Syndrome</condition>
  <condition>Refractory Hypoxemia</condition>
  <arm_group>
    <arm_group_label>Conventional ARDS treatment group</arm_group_label>
    <description>Patients who they or their 1st degree relative refuse to initiate ECMO. They will receive conventional ARDS treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ECMO group</arm_group_label>
    <description>Patients who ECMO is initiated for treat refractory hypoxemia. They will receive conventional ARDS treatment and ECMO support</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Extra Corporeal Membrane Oxygenator (ECMO)</intervention_name>
    <description>Two cannular will be inserted via femoral vein or internal jugular vein and connect with blood pump and membrane oxygenation.</description>
    <arm_group_label>ECMO group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult severe ARDS with refractory hypoxemia
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed ARDS according to Berlin criteria

          -  Refractory hypoxemia: PaO2/FiO2 &lt;100 with FiO2 &gt;90% despite optimal mechanical
             ventilator support and paralytic agent infusion

          -  Hypoxemia persist for at least 2 hours

        Exclusion Criteria:

          -  Terminally ill patient

          -  Patient who sign for do not resuscitation

          -  Metastatic malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Surat Tongyoo, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mahidol University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Surat Tongyoo, Dr.</last_name>
    <phone>0820137771</phone>
    <email>surat.ton@mahidol.ac.th</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Chairat Permpikul, Dr.</last_name>
    <email>chairat.per@mahidol.ac.th</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkoknoi</city>
        <state>Bangkok</state>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Surat Tongyoo, Dr.</last_name>
      <phone>820137771</phone>
      <email>surat.ton@mahidol.ac.th</email>
    </contact>
    <contact_backup>
      <last_name>Chairat Permpikul, Dr.</last_name>
      <email>chairat.per@mahidol.ac.th</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Thailand</country>
  </location_countries>
  <reference>
    <citation>Australia and New Zealand Extracorporeal Membrane Oxygenation (ANZ ECMO) Influenza Investigators, Davies A, Jones D, Bailey M, Beca J, Bellomo R, Blackwell N, Forrest P, Gattas D, Granger E, Herkes R, Jackson A, McGuinness S, Nair P, Pellegrino V, Pettil√§ V, Plunkett B, Pye R, Torzillo P, Webb S, Wilson M, Ziegenfuss M. Extracorporeal Membrane Oxygenation for 2009 Influenza A(H1N1) Acute Respiratory Distress Syndrome. JAMA. 2009 Nov 4;302(17):1888-95. doi: 10.1001/jama.2009.1535. Epub 2009 Oct 12.</citation>
    <PMID>19822628</PMID>
  </reference>
  <reference>
    <citation>Noah MA, Peek GJ, Finney SJ, Griffiths MJ, Harrison DA, Grieve R, Sadique MZ, Sekhon JS, McAuley DF, Firmin RK, Harvey C, Cordingley JJ, Price S, Vuylsteke A, Jenkins DP, Noble DW, Bloomfield R, Walsh TS, Perkins GD, Menon D, Taylor BL, Rowan KM. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A(H1N1). JAMA. 2011 Oct 19;306(15):1659-68. doi: 10.1001/jama.2011.1471. Epub 2011 Oct 5.</citation>
    <PMID>21976615</PMID>
  </reference>
  <reference>
    <citation>Peek GJ, Mugford M, Tiruvoipati R, Wilson A, Allen E, Thalanany MM, Hibbert CL, Truesdale A, Clemens F, Cooper N, Firmin RK, Elbourne D; CESAR trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet. 2009 Oct 17;374(9698):1351-63. doi: 10.1016/S0140-6736(09)61069-2. Epub 2009 Sep 15. Erratum in: Lancet. 2009 Oct 17;374(9698):1330.</citation>
    <PMID>19762075</PMID>
  </reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 22, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 24, 2019</study_first_posted>
  <last_update_submitted>July 25, 2019</last_update_submitted>
  <last_update_submitted_qc>July 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Veno-venous ECMO</keyword>
  <keyword>Severe ARDS</keyword>
  <keyword>Refractory Hypoxemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Hypoxia</mesh_term>
    <mesh_term>Shock</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data will be shared with no patient identified number.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Data will be available per request</ipd_time_frame>
    <ipd_access_criteria>For meta-analysis</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

